Prostate cancer in Asia: a collaborative report

Asian Journal of Urology, 2014, 1 (1): 15-27 doi:

Asian Focus

Prostate cancer in Asia: a collaborative report

Rui Chen¹, Shancheng Ren¹, Chinese Prostate Cancer Consortium¹, Ming Kwong Yiu², Ng Chi Fai³, Wai Sam Cheng⁴, Lap Hong Ian⁵, Seiji Naito⁶, Tadashi Matsuda⁷, Elijah Kehinde⁸, Ali Kural⁹, Jason Yichun Chiu¹⁰, Rainy Umbas¹¹, Qiang Wei¹², Xiaolei Shi¹, Liqun Zhou¹³, Jian Huang¹⁴, Yiran Huang¹⁵, Liping Xie¹⁶, Lulin Ma¹⁷, Changjun Yin¹⁸, Danfeng Xu¹⁹, Kexin Xu²⁰, Zhangqun Ye²¹, Chunxiao Liu²², Dingwei Ye²³, Xin Gao²⁴, Qiang Fu²⁵, Jianquan Hou²⁶, Jianlin Yuan²⁷, Dalin He²⁸, Tiejun Pan²⁹, Qiang Ding³⁰, Fengshuo Jin³¹, Benkang Shi³², Gongxian Wang³³, Xiuheng Liu³⁴, Dongwen Wang³⁵, Zhoujun Shen³⁶, Xiangbo Kong³⁷, Wanhai Xu³⁸, Yaoliang Deng³⁹, Haibo Xia⁴⁰, Alexa N.Cohen⁴¹, Xu Gao¹, Chuanliang Xu¹, Yinghao Sun¹

1. Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China;
2. Department of Surgery, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China;
3. Division of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China;
4. Department of Urology, Singapore General Hospital, Singapore;
5. Department of Urology, Centro Hospitalar Conde de Sâo Januário (CHCSJ) Hospital, Macau, China;
6. Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
7. Department of Urology and Andrology, Hirakata Hospital, Kansai Medical University, Osaka, Japan;
8. Department of Surgery, Kuwait University, Kuwait;
9. Department of Urology, Istanbul Acibadem University, Istanbul, Turkey;
10. Department of Urology, Taipei City Hospital, National Yang-Ming University, Taipei, Taiwan, China;
11. Division of Urology, Department of Surgery, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia;
12. Department of Urology, West China Hospital, Sichuan University, Chengdu, China;
13. Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China;
14. Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;
15. Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;
16. Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;
17. Department of Urology, Peking University Third Hospital, Beijing, China;
18. State Key Laboratory of Reproductive Medicine, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China;
19. Department of Urology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China;
20. Peking University People's Hospital, Beijing, China;
21. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;
22. Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China;
23. Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai, China;
24. Department of Urology, 3rd Hospital of Sun Yat-Sen University, Guangzhou, China;
25. Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, China;
26. The First Affiliated Hospital of Soochow University, Suzhou, China;
27. Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China;
28. Department of Urology, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, China;
29. Department of Urology, Wuhan General Hospital of Guangzhou Military Command, Wuhan, China;
30. Department of Urology, Huashan Hospital, Fudan University, Shanghai, China;
31. Department of Urology, Daping Hospital, Chongqing, China;
32. Department of Urology, Qilu Hospital of Shandong University, Jinan, China;
33. Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China;
34. Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China;
35. Department of Urology, First Clinical Medical College, Shanxi Medical University, Taiyuan, China;
36. Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;
37. Department of Urinary Surgery, China-Japan Union Hospital, Jilin University, Changchun, China;
38. Department of Urology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China;
39. The First Affiliated Hospital of Guangxi Medical University, Nanning, China;
40. Department of Urology, Affiliated Hospital of Chifeng College, Chifeng, China;
41. Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA

Abstract
Related Citation (15)

[1]	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA:Cancer J Clin 2013; 63: 11-30.
[2]	Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, BrawleyO, et al. International variation in prostate cancer incidence andmortality rates. Eur Urol 2012; 61: 1079-92.
[3]	Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and MortalityWorldwide: IARC CancerBase No. 11 [Internet]. Lyon, France:International Agency for Research on Cancer; 2013. Available from:http://globocan.iarc.fr, accessed on 2014/08/28.
[4]	Pramesh CS, Badwe RA, Borthakur BB, Chandra M, Raj EH,Kannan T, et al. Delivery of affordable and equitable cancer care inIndia. Lancet Oncol 2014; 15: e223-33.
[5]	Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Globalcancer statistics. CA: Cancer J Clin 2011; 61: 69-90.
[6]	Ito K. Prostate cancer in Asian men. Nat Rev Urol 2014; 11:197-212.
[7]	He JCW. Chinese Cancer Registry Annual Report 2012. Beijing:China Military Medical Science Press, 2013.
[8]	Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancerstatistics in Korea: incidence, mortality, survival, and prevalence in2011. Cancer Res Treat 2014; 46: 109-23.
[9]	Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C,Esgueva R, et al. TMPRSS2-ERG gene fusion prevalence and classare significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011; 71: 489-97.
[10]	Ren S, Peng Z, Mao JH, Yu Y, Yin C, Gao X, et al. RNA-seqanalysis of prostate cancer in the Chinese population identifiesrecurrent gene fusions, cancer-associated long noncoding RNAs andaberrant alternative splicings. Cell Res 2012; 22: 806-21.
[11]	Rubin MA, Maher CA, Chinnaiyan AM. Common generearrangements in prostate cancer. J Clin Oncol 2011; 29: 3659-68.
[12]	Leinonen KA, Saramaki OR, Furusato B, Kimura T, Takahashi H,Egawa S, et al. Loss of PTEN is associated with aggressive behaviorin ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev2013; 22: 2333-444.
[13]	Konishi N, Hiasa Y, Tsuzuki T, Tao M, Enomoto T, Miller GJ.Comparison of ras activation in prostate carcinoma in Japanese andAmerican men. Prostate 1997; 30: 53-7.
[14]	Ren G, Liu X, Mao X, Zhang Y, Stankiewicz E, Hylands L, et al.Identification of frequent BRAF copy number gain and alterations ofRAF genes in Chinese prostate cancer. Genes Chromosomes Cancer2012; 51: 1014-23.
[15]	Eeles RA, Olama AA, Benlloch S, Saunders EJ, LeongamornlertDA, Tymrakiewicz M, et al. Identification of 23 new prostate cancersusceptibility loci using the iCOGS custom genotyping array. NatGenet 2013; 45: 385-91, 91e1-2.
[16]	Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N,Kawaguchi T, et al. Genome-wide association study identifiesfive new susceptibility loci for prostate cancer in the Japanesepopulation. Nat Genet 2010; 42: 751-4.
[17]	Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, Kubo M,et al. Common variants at 11q12, 10q26 and 3p11.2 are associatedwith prostate cancer susceptibility in Japanese. Nat Genet 2012; 44:426-9, S1.
[18]	Xu J, Mo Z, Ye D, Wang M, Liu F, Jin G, et al. Genome-wideassociation study in Chinese men identifies two new prostate cancerrisk loci at 9q31.2 and 19q13.4. Nat Genet 2012; 44: 1231-5.
[19]	Shan J, Al-Rumaihi K, Rabah D, Al-Bozom I, Kizhakayil D,Farhat K, et al. Genome scan study of prostate cancer in Arabs:identification of three genomic regions with multiple prostate cancersusceptibility loci in Tunisians. J Transl Med 2013; 11: 121.
[20]	Nam KC, Jo C, Lee M. Meat products and consumption culture inthe East. Meat Sci 2010; 86: 95-102.
[21]	Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, etal. Cancer incidence rates among South Asians in four geographicregions: India, Singapore, UK and US. Int J Epidemiol 2008; 37:147-60.
[22]	Zhang J, Dhakal IB, Zhao Z, Li L. Trends in mortality from cancersof the breast, colon, prostate, esophagus, and stomach in East Asia:role of nutrition transition. Eur J Cancer Prev 2012; 21: 480-9.
[23]	Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D,Church TR, et al. Prostate cancer screening in the randomizedProstate, Lung, Colorectal, and Ovarian Cancer Screening Trial:mortality results after 13 years of follow-up. J Natl Cancer Inst2012; 104: 125-32.
[24]	Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, NelenV, et al. Screening and prostate-cancer mortality in a randomizedEuropean study. N Engl J Med 2009; 360: 1320-8.
[25]	Liu ZY, Sun YH, Xu CL, Gao X, Zhang LM, Ren SC. Age-specificPSA reference ranges in Chinese men without prostate cancer. AsianJ Androl 2009; 11: 100-3.
[26]	Lim J, Bhoo-Pathy N, Sothilingam S, Malek R, Sundram M, HishamBahadzor B, et al. Ethnicity is an independent determinant of agespecificPSA level: findings from a multiethnic Asian setting. PLoSOne 2014; 9: e104917.
[27]	Lin TP, Huang WJ, Chen KK. Differentiation of benign prostatichyperplasia from prostate cancer using prostate specific antigendynamic profile after transrectal prostate biopsy. J Urol 2004; 171:2226-9.
[28]	Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ,Panser LA, et al. Serum prostate-specific antigen in a communitybasedpopulation of healthy men. Establishment of age-specificreference ranges. JAMA 1993; 270: 860-4.
[29]	Wu TT, Huang JK. The clinical usefulness of prostate-specificantigen (PSA) level and age-specific PSA reference ranges fordetecting prostate cancer in Chinese. Urol Int 2004; 72: 208-11.[30] Choi YD, Kang DR, Nam CM, Kim YS, Cho SY, Kim SJ, et al. Agespecificprostate-specific antigen reference ranges in Korean men.Urology 2007; 70: 1113-6.
[31]	Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA,Masumori N, et al. Serum prostate-specific antigen in a communitybasedpopulation of healthy Japanese men: lower values than forsimilarly aged white men. Br J Urol 1995; 75: 347-53.
[32]	Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J. Diagnosticsignificance of prostate specific antigen and the development of amass screening system for prostate cancer. J Urol 1995; 154: 1085-9.
[33]	Malati T, Kumari GR. Racial and ethnic variation of PSA in globalpopulation: age specific reference intervals for serum prostatespecific antigen in healthy South Indian males. Indian J ClinBiochem 2004; 19: 132-7.
[34]	Abdrabo AA, Fadlalla AI, Fadl-Elmula IM. Age-specific referencerange for serum prostate-specific antigen in Sudanese men. SaudiMed J 2011; 32: 930-2.
[35]	Kamal BA, Ali GA, Taha SA. Prostate specific antigen referenceranges in Saudi men. Saudi Med J 2003; 24: 665-8.
[36]	Saw S, Aw TC. Age-related reference intervals for free and totalprostate-specific antigen in a Singaporean population. Pathology2000; 32: 245-9.
[37]	Kehinde EO, Mojiminiyi OA, Sheikh M, Al-Awadi KA, Daar AS,Al-Hunayan A, et al. Age-specific reference levels of serum prostatespecificantigen and prostate volume in healthy Arab men. BJU Int2005; 96: 308-12.
[38]	Khezri AA, Shirazi M, Ayatollahi SM, Lotfi M, Askarian M, AriafarA, et al. Age specific reference levels of serum prostate-specificantigen, prostate volume and prostate specific antigen density inhealthy Iranian men. Iran J Immunol 2009; 6: 40-8.
[39]	Takahashi H, Epstein JI, Wakui S, Yamamoto T, Furusato B, ZhangM. Differences in prostate cancer grade, stage, and location inradical prostatectomy specimens from United States and Japan.Prostate 2014; 74: 321-5.
[40]	Peyromaure M, Debre B, Mao K, Zhang G, Wang Y, Sun Z, et al.Management of prostate cancer in China: a multicenter report of 6institutions. J Urol 2005; 174: 1794-7.
[41]	Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones JS, KattanMW, et al. The relationship between prostate-specific antigen andprostate cancer risk: The Prostate Biopsy Collaborative Group. ClinCancer Res 2010; 16: 4374-81.
[42]	Kimura T. East meets West: ethnic differences in prostate cancerepidemiology between East Asians and Caucasians. Chin J Cancer2012; 31: 421-9.
[43]	Terao C, Terada N, Matsuo K, Kawaguchi T, Yoshimura K, HayashiN, et al. A genome-wide association study of serum levels ofprostate-specific antigen in the Japanese population. J Med Genet2014; 51: 530-6.
[44]	Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A,Mulders PF, et al. Clinical utility of the PCA3 urine assay inEuropean men scheduled for repeat biopsy. Eur Urol 2008; 54:1081-8.
[45]	Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G,Maccagnano C, et al. Prostate-specific antigen (PSA) isoform p2PSAsignificantly improves the prediction of prostate cancer at initialextended prostate biopsies in patients with total PSA between 2.0and 10 ng/ml: results of a prospective study in a clinical setting. EurUrol 2011; 60: 214-22.
[46]	Na R, Ye D, Liu F, Chen H, Qi J, Wu Y, et al. Performance ofserum prostate-specific antigen isoform [-2]proPSA (p2PSA) andthe prostate health index (PHI) in a Chinese hospital-based biopsypopulation. Prostate 2014;74:1569-75.
[47]	Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP,McNicholas T, et al. Clinical performance of serum prostate-specificantigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSAand the prostate health index (PHI), in men with a family historyof prostate cancer: results from a multicentre European study, thePROMEtheuS project. BJU Int 2013; 112: 313-21.
[48]	Ochiai A, Okihara K, Kamoi K, Iwata T, Kawauchi A, Miki T, et al.Prostate cancer gene 3 urine assay for prostate cancer in Japanesemen undergoing prostate biopsy. Int J Urol 2011; 18: 200-5.
[49]	Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, MurayamaS, et al. Clinical utility of the prostate cancer gene 3 (PCA3) urineassay in Japanese men undergoing prostate biopsy. BJU Int 2013;111: 928-33.
[50]	Ng CF, Yeung R, Chiu PK, Lam NY, Chow J, Chan B. The role ofurine prostate cancer antigen 3 mRNA levels in the diagnosis ofprostate cancer among Hong Kong Chinese patients. Hong KongMed J 2012; 18: 459-65.
[51]	Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, et al. Thediagnostic value of PCA3 gene-based analysis of urine sedimentsafter digital rectal examination for prostate cancer in a Chinesepopulation. Exp Mol Pathol 2011; 90: 97-100.
[52]	Na R, Ye D, Liu F, Chen H, Qi J, Wu Y, et al. Performance ofserum prostate-specific antigen isoform [-2]proPSA (p2PSA) andthe prostate health index (PHI) in a Chinese hospital-based biopsypopulation. Prostate 2014; 74: 1569-75.
[53]	Ng CF, Chiu PK, Lam NY, Lam HC, Lee KW, Hou SS. The ProstateHealth Index in predicting initial prostate biopsy outcomes in Asianmen with prostate-specific antigen levels of 4-10 ng/mL. Int UrolNephrol 2014; 46: 711-7.
[54]	Ito K, Miyakubo M, Sekine Y, Koike H, Matsui H, Shibata Y, etal. Diagnostic significance of [-2]pro-PSA and prostate dimensionadjustedPSA-related indices in men with total PSA in the 2.0-10.0ng/mL range. World J Urol 2013; 31: 305-11.
[55]	Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, et al. Long non-codingRNA metastasis associated in lung adenocarcinoma transcript 1derived miniRNA as a novel plasma-based biomarker for diagnosingprostate cancer. Eur J Cancer 2013; 49: 2949-59.
[56]	Jiang H, Liu F, Wang Z, Na R, Zhang L, Wu Y, et al. Prediction ofprostate cancer from prostate biopsy in Chinese men using a geneticscore derived from 24 prostate cancer risk-associated SNPs. Prostate2013; 73: 1651-9.
[57]	Ueda K, Tatsuguchi A, Saichi N, Toyama A, Tamura K, Furihata M,et al. Plasma low-molecular-weight proteome profiling identifiedneuropeptide-Y as a prostate cancer biomarker polypeptide. JProteome Res 2013; 12: 4497-506.
[58]	Li XM, Zhang L, Li J, Li Y, Wang HL, Ji GY, et al. Measurement ofserum zinc improves prostate cancer detection efficiency in patientswith PSA levels between 4 ng/mL and 10 ng/mL. Asian J Androl2005; 7: 323-8.
[59]	Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K,et al. Circulating long non-coding RNAs in plasma of patients withgastric cancer. Anticancer Res 2013; 33: 3185-93.
[60]	Reiner WG, Walsh PC. An anatomical approach to the surgicalmanagement of the dorsal vein and Santorini's plexus during radicalretropubic surgery. J Urol 1979; 121: 198-200.
[61]	Schuessler WW, Schulam PG, Clayman RV, Kavoussi LR.Laparoscopic radical prostatectomy: initial short-term experience.Urology 1997; 50: 854-7.
[62]	Gao X, Qiu JG, Wang JG. Laparoscopic radical prostatectomy:report of the first case. Chin J Urol 2002; 23: 59.
[63]	Kawabata G, Hara I, Hara S, Isotani S, Sakai Y, Wada Y, et al.
	[Laparoscopic radical prostatectomy: initial 17 case report]. Nihon Hinyokika Gakkai zasshi 2001; 92: 647-55.
[64]	Wolfram M, Brautigam R, Engl T, Bentas W, Heitkamp S, OstwaldM, et al. Robotic-assisted laparoscopic radical prostatectomy: theFrankfurt technique. World J Urol 2003; 21: 128-32.
[65]	Wang W, Gao J, Xu X, Dong J, Zhu J. Extraperitoneal robot-assistedlaparoscopic radical prostatectomy. Proceedings of the 16th ChinsesUrology Association Annual Meeting, Chengdu, China, Sep 18th,2009.
[66]	Chen MK, Luo Y, Zhang H, Qiu JG, Wen XQ, Pang J, et al.Laparoscopic radical prostatectomy plus extended lymph nodesdissection for cases with non-extra node metastatic prostate cancer:5-year experience in a single Chinese institution. J Cancer Res ClinOncol 2013; 139: 871-8.
[67]	Zheng T, Zhang X, Ma X, Li HZ, Gao JP, Cai W, et al. Oncologicaland functional results of extraperitoneal laparoscopic radicalprostatectomy. Oncol Lett 2012; 4: 351-7.
[68]	Wen XQ, Huang WT, Situ J, Hu C, Ye CW, Gao X. Single-portlaparoscopic radical prostatectomy: initial experience and technicalpoints to reduce its difficulties. Chin Med J 2011; 124: 4092-5.
[69]	Namiki S, Kaiho Y, Mitsuzuka K, Saito H, Yamada S, Nakagawa H,et al. Long-term quality of life after radical prostatectomy: 8-Yearlongitudinal study in Japan. Int J Urol 2014; doi: 10.1111/iju.12586.
	[Epub ahead of print]
[70]	Mishra S, Agrawal V, Khatri N, Sharma R, Kurien A, Ganpule A,et al. Laparoscopic radical prostatectomy: oncological outcomeanalysis from a single-center Indian experience of 6 years. Indian JUrol 2012; 28: 32-6.
[71]	Koo KC, Tuliao P, Yoon YE, Chung BH, Hong SJ, Yang SC, et al.Robot-assisted radical prostatectomy in the Korean population: a5-year propensity-score matched comparative analysis versus openradical prostatectomy. Int J Urol 2014; 21: 781-5.
[72]	Gao X, Pang J, Si-tu J, Luo Y, Zhang H, Li LY, et al. Single-porttransvesical laparoscopic radical prostatectomy for organ-confinedprostate cancer: technique and outcomes. BJU Int 2013; 112: 944-52.
[73]	Lim SK, Kim KH, Shin TY, Han WK, Chung BH, Hong SJ, et al.Retzius-sparing robot-assisted laparoscopic radical prostatectomy:combining the best of retropubic and perineal approaches. BJU Int2014; 114: 236-44.
[74]	Ficarra V, Cavalleri S, Novara G, Aragona M, Artibani W. Evidencefrom robot-assisted laparoscopic radical prostatectomy: a systematicreview. Eur Urol 2007; 51: 45-56.
[75]	Denis LJ. Staging and prognosis of prostate cancer. Eur Urol 1993;24 Suppl 2: 13-8.
[76]	Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, etal. Prevalence of prostate cancer on autopsy: cross-sectional studyon unscreened Caucasian and Asian men. J Natl Cancer Inst 2013;105: 1050-8.